Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Third Quarter Financial Results on November 9, 2021

Ligand to Report Third Quarter Financial Results on November 9, 2021

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic using Ligand's BEPro Technology™

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand's BEPro Technology™

Ligand has a cornucopia of productive assets. Ligand has one cash cow, Captisol, that has been generating outsized revenues.

Ligand's Ailing Remdesivir Cash Cow

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China's National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin's lymphoma (cHL). GloriaBio has development and commercialization rights in China with respect to zimberelimab through a subl

Ligand's Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q2 2021 Results - Earnings Call Transcript

Ligand (LGND) delivered earnings and revenue surprises of 12.41% and 15.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports Second Quarter 2021 Financial Results

Ligand Reports Second Quarter 2021 Financial Results

PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into Ligand's OmniAb ® and xPloration™ antibody discovery platforms.

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Partner Jazz Pharmaceuticals Launches RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

SAN DIEGO--(BUSINESS WIRE)---- $LGND--Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

Ligand helps other biopharma drug developers with its various platforms.

Ligand: 2021 Is Pivotal

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND #earnings--Ligand to Report Second Quarter Financial Results on July 29, 2021

Ligand to Report Second Quarter Financial Results on July 29, 2021

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $LGND--Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors

Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors

Ligand (LGND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ligand (LGND) Moves 3.1% Higher: Will This Strength Last?

SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia, today emerged from stealth mode with a $47 million Series A financing from Versant Ventures and RA Capital Management. Proceeds from the financing will be utilized to progress the company's lead asset, an eyedrop formulation of aceclidine, towards an NDA submission for the treatment of presbyopia. Presbyopia impacts

LENZ Therapeutics Debuts With $47 Million Series A Financing

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?

NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb® Platform, a multi-species antibody discovery platform, to generate highly diversified, fully human antibodies that are optimized in vivo for immunogenicity, manufacturability and efficacy. Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.

Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q1 2021 Results - Earnings Call Transcript

Shares of Ligand Pharmaceuticals (NASDAQ:LGND) fell 7% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.43% over the past year to $1.41, which beat the estimate of $1.12.

Recap: Ligand Pharmaceuticals Q1 Earnings

SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand Reports First Quarter 2021 Financial Results

News for Ligand Pharmaceuticals Stock (LGND)